

STROKE MODEL

[New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.](#)

Roncal C, Martinez de Lizarrondo S, Salicio A, Chevillet A, Rodriguez JA, Rosell A, Couraud PO, Weksler B, Montaner J, Vivien D, Páramo JA, Orbe J. Cardiovasc Res. 2017 Aug 1;113(10):1219-1229. doi: 10.1093/cvr/cvx069.

[Recent progress in translational research on neurovascular and neurodegenerative disorders.](#)

Demuth HU, Dijkhuizen RM, Farr TD, Gelderblom M, Horsburgh K, Iadecola C, Mcleod DD, Michalski D, Murphy TH, Orbe J, Otte WM, Petzold GC, Plesnila N, Reiser G, Reymann KG, Rueger MA, Saur D, Savitz SI, Schilling S, Spratt NJ, Turner RJ, Vemuganti R, Vivien D, Yepes M, Zille M, Boltze J; ISN&N meeting contributors. Restor Neurol Neurosci. 2017;35(1):87-103. doi: 10.3233/RNN-160690. Review.

[Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis.](#)

Orset C, Haelewyn B, Allan SM, Ansar S, Campos F, Cho TH, Durand A, El Amki M, Fatar M, Garcia-Yébenes I, Gauberti M, Grudzinski S, Lizasoain I, Lo E, Macrez R, Margail I, Maysami S, Meairs S, Nighoghossian N, Orbe J, Paramo JA, Parienti JJ, Rothwell NJ, Rubio M, Waeber C, Young AR, Touzé E, Vivien D. Stroke. 2016 May;47(5):1312-1318. doi: 10.1161/STROKEAHA.116.012238.

[Activated protein C \$\beta\$ -glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury.](#)

Gleeson EM, Dichiara MG, Salicio A, Quinn LM, Drakeford C, Russell SE, Walsh PT, Orbe J, Hermida J, Smith OP, O'Donnell JS, Montes R, Preston RJ. Blood. 2015 Aug 13;126(7):915-9. doi: 10.1182/blood-2015-03-632877.

[Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.](#)

Orbe J, Alexandru N, Roncal C, Belzunce M, Bibiot P, Rodriguez JA, Meijers JC, Georgescu A, Paramo JA. Thromb Res. 2015 Aug;136(2):445-50. doi: 10.1016/j.thromres.2015.06.010.

[Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.](#)

Orbe J, Barrenetxe J, Rodriguez JA, Vivien D, Orset C, Parks WC, Birkland TP, Serrano R, Purroy A, Martinez de Lizarrondo S, Angles-Cano E, Páramo JA. Circulation. 2011 Dec 20;124(25):2909-19. doi: 10.1161/CIRCULATIONAHA.111.047100.